

ICI Rende | Pharmaceutical Idi | Pharmaceutical Industry Galenica Senese | Ipsen | Iqvia | Ies Italy | Ist. Farm. Organic Stroder | De Angeli Institute | Ganassini Institute | Gentili | Institute Istituto Luso Farmaco d'Italia | Italchimici | Italfarmaco | Italy | ITEL Telecommunications | Janssen-Cilag | Johnson & Johnson Medical | Kedrion | Kyowa Kirin | L. Molteni & C. F.lli Alitti | Baldacci | Laboratories Guidotti | Laboratories Pharmaceutical Laboratory C.T. | Pharmaceutical Laboratory S.I.T. | Therapeutic Laboratory M.R. | Leo Pharma | Lifepharm | Lofarma | Lundbeck Italy | Malay Institute Farm. | Mastelli | Master Pharma | Merck Serono | Mercurio Pharma | Mitim | Monico | Msd Italy | Mundipharma Pharmaceuticals | Mylan Italia to Viatris Company | Neopharmed Dear | Nerviano Medical Sciences | Noos | Norgine Italy | Novartis Farma | Novo Nordisk | Octapharma Italy | Omikron Italy | Opella Healthcare Italy | Organon Italia | Otsuka Pharmaceutical Italy | Patheon Italy | Pfizer UK | Pfizer | Pharmafar | Pharmanutra | Philogen | Piam Pharmaceuticals | Pierre Fabre Pharma | Pierrel | Polichem | Polypharma | Promedica | Recordati Ind.Chim.Farm. | Recordati Rare Diseases Italy | Roche | Sanofi | Savio Pharma Italy | Scharper | Servier Italia | Shionogi | Sifi | Simesa | Sintesy Pharma | Know. Se.Pharm | Company Antibiotic Products | Sofar | Stewart Italy | Takeda Italy | Takeda Manufacturing ITALIA | Temmler Italy | Teva Italy | Tubilux Pharma | Ucb Pharma | Valeas Ind. Chimica and Farmac. | Valpharma International | Vertex Pharmaceuticals | Vifor Pharma Italia | Viiv Healthcare | Visufarma | Welcome Pharma | Wyeth Lederle | Zambon | Zeta Pharmaceuticals



FARMINDUSTRIA

Largo del Nazareno 3/8 - 00187 Roma

T: 06 675801

Avenue de la Joyeuse Entrée 1 - B1040 Bruxelles

T: +32 2 2861255

farmindustria@farmindustria.it

www.farmindustria.it



Publication closed with data and information
as of 30 June 2022

PHARMACEUTICAL INDUSTRY IN ITALY

FACTS AND FIGURES



MEMBER COMPANIES

A.C.R.A.F. Az Chim. Reunite Angelini Francesco | A. Menarini Ind. Farm. Get | Abbvie | Abiogen Pharma | Acarpia Pharmaceuticals | Adare Pharmaceuticals | Addenda Pharma | Advanced Accelerator Applications Italy | Aeffe Pharmaceuticals | Italian aerosol service | Aesculapius Pharmaceuticals | Aesica Pharmaceuticals | Alexion Pharma Italy | Alfa Biotech | Alphasigma | Alk-Abelló | Allergan | Alliance Pharma | Almirall | Altergon Italy | Amgen | Aptuit | Astellas Pharma | Astrazeneca | Avara Liscate Pharmaceutical Services | Bausch & Lomb Iom | Bayer Healthcare Manufacturing | Bayer | Bial Italia | Biogen UK | Biologici Italia Laboratories | Biopharma | Biotest Italia | Boehringer Ingelheim Italy | Bracco Imaging Italia | Bristol-Myers Squibb | Bruschetti | Bsp Pharmaceuticals | C.O.C. Pharmaceuticals | Catalent Italy | Celgene | Chiesi Farmaceutici | Chiesi Italy | Corden Pharma Latina | Corden Pharma | Cosmos | Crucell Italy | Cso Pharmitalia | D.m.g. Italy | Daiichi Sankyo Italy | Dompé Pharmaceuticals | Doppel Pharmaceuticals | Ecupharma | Eisai | Eli Lilly Italy | E-Pharma Trento | Pharmaceutical Products | Euromed | F.I.R.M.A. | Damor | Pharmaceuticals Farmaka | Farmalabor | Farmila-Thea Pharmaceuticals | Farmitalia Ind. Chemist Farmac. | Fatro | Ferring | Fine Foods & Pharmaceuticals N.T.M. | Fulton Medicines | Galapagos Biopharma Italy | Galderma Italy | Galileo Research | Gb Pharma | Ge Healthcare | Gentium | Gilead Sciences | Giuliani | Glaxosmithkline Manufacturing | Glaxosmithkline | Glaxosmithkline Vaccines | Grifols Italia | Grünenthal Italy | Guerbet | Hikma Italy | I.B.I. Giovanni Lorenzini | I.B.N. Savio | I.bir.n. - Ist. Biotherapy Naz. | IBSA Farmaceutici Italia |

RESEARCH AND INNOVATION FOR PEOPLE

OUR STRENGTH: PEOPLE

ASSET OF THE COUNTRY FOR GROWTH AND HEALTH

ALLIES IN THE FIGHT AGAINST THE CLIMATE CRISIS



EVER MORE HOPES OF CURES

In 2021, **84 new medicines** are authorized worldwide. This figure is the highest in the last 10 years (55 per year on average). More than 18 thousand products currently under study and some of them will actually become therapies, thus making the **hope of cure** for patients and of increasingly personalized medicine always more concrete.



VACCINES AND MEDICINES AGAINST COVID-19

Thanks to pharmaceutical research, regulatory innovations and more than 200 collaborations between companies and public research centers, 13 billion doses were produced in a year and **two-thirds of the world population received at least one**. Italy has a key role: it is among the top four EU countries for vaccine **exports**, it is a hub for the production of monoclonal and antiviral antibodies and among the top list countries for scientific publications globally.



THE CLOCK OF LIFE

After the dramatic reversal due to Covid-19, in 2021 the clock of life has returned to go round in the right direction and the average life span has widened by **more than 6 months in 1 year**. This is an achievement to be consolidated, with even more research and by recovering the health services that have been postponed due to the pandemic emergency.



QUALITY EMPLOYMENT

There are **67 thousand people** working in the Pharma industry, 147 thousand taking into consideration also direct suppliers. In the last 5 years, pharma has been the first sector in Italy for employment growth (+9% compared to +1% of the average), thanks to its **dynamism** and to the **sustainable and inclusive development models** of its companies. 90% of our employees are university or high school graduates. Gender equality is already a reality: 43% of our employees are women (29% on average in industry), many with leadership roles.



YOUTH AND TRAINING

More and more young people. In the last 5 years, the under35s **have grown by 13%**. Companies are acquiring new skills, which grow constantly after recruitment through training and professional development, in the name of multidisciplinary and soft skills.



CORPORATE WELFARE FOR PEOPLE

The Pharma sector is characterized by a corporate welfare for people: **work life balance**, enhancement of diversity, training, healthcare, assistance to elderly family members and measures to support parenthood.



INDUSTRIAL VALUE

With **€34.4 billion** in **production**, the pharmaceutical industry in Italy is a strategic asset of the economy. A leader in Europe together with Germany and France, thanks to **exports increased** by 117% in the last ten years, above the EU average (112%), in particular thanks to the increase in products with higher added value.



INVESTMENTS, INNOVATION AND DIGITAL TRANSITION

In 2021, investments in Italy totaled **€3.1 billion**, €1.4 billion of which in high-tech plants and €1.7 billion in R&D. Every year €700 million is invested in **clinical research**, focused on hospitals, with great benefits for access to new treatments, growth of skills and savings for the NHS. Pharma is the first sector for **open innovation**. Digital transition is racing ahead. In the last 2 years, 284 telemedicine solutions have been implemented by local health agencies, often in collaboration with companies. 82% of doctors are ready to collaborate with companies for digital projects.



MORE ATTRACTIVENESS FOR GROWTH

Between 2021 and 2026, the world pharmaceutical companies will invest €1.3 trillion in R&D, the largest such investment on the planet. An opportunity for **growth and development** that Italy can seize, thanks to its scientific and industrial excellence, if it implements policies that increase the attractiveness and competitiveness of the system.



ECOLOGICAL TRANSITION

The pharmaceutical industry is committed to ecological transition, also through important investments aimed at the **efficient management of resources**: water treatment, reduction of waste and the use of plastic.



EFFICIENCY

In ten years, our sector in Italy has **reduced energy consumption** by 44%, a percentage that rises to 51% for those relevant for atmospheric emissions. Achievements resulting from growing investments in **green technologies**: the differential of investments in environmental protection per employee compared to the national average is +150%, and it rises above 200% for investments in technologies aimed at the prevention of pollution, which eliminate or reduce pollution at the source of the production process.



CIRCULAR APPROACH

Pharmaceutical companies in Italy are at the forefront of the "circular approach", a model that generates innovation, increases **efficiency and competitiveness**, and is good for businesses, the environment and the communities of the territories in which they operate.